Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently conducting a Phase III clinical trial in patients with Prader Willi Syndrome (PWS) with its lead candidate, DCCR, a once-daily oral tablet.
For more information about the ongoing Phase III study, please visit https://clinicaltrials.gov/ct2/show/NCT03440814?term=dccr&recrs=a&rank=1
For more information about
LifeSci Advisors, LLC
Source: Soleno Therapeutics